We understand the importance of finding reliable investment opportunities, especially in the pharmaceutical sector. Investors often seek stability and growth potential, and one way to achieve this is by investing in pharma stocks with high dividend yields.
In this article, we’ll delve into some of the top pharma stocks with high dividend yields known for their consistent dividend payouts and solid performance.
Understanding Dividend Yield
Before diving into specific stocks, let’s clarify what dividend yield represents. It’s calculated by dividing the annual dividend per share by the stock’s current market price and is often expressed as a percentage.
Top Pharma Stocks with High Dividend Yield
Within the realm of pharmaceuticals, companies undertake the crucial task of discovering, developing, manufacturing, and marketing drugs for both human and veterinary use.
This multifaceted sector encompasses innovators and research firms dedicated to pioneering new drug discoveries, alongside generic drug manufacturers producing cost-effective alternatives to branded medications.
One of the primary avenues through which pharmaceutical companies enhance shareholder value is by distributing dividends, providing investors with a tangible return on their investment. The dividend yield, a key metric, serves as a yardstick for investors seeking a consistent and reliable income stream.
In this comprehensive exploration, we embark on a journey through the pharmaceutical landscape to uncover top pharma stocks with high dividend yields, thereby presenting lucrative investment opportunities.
Also Read : Best Automobile Penny Stocks in India
#1 Sanofi India
Sanofi India, a subsidiary of the renowned French multinational pharmaceutical and healthcare conglomerate Sanofi, has been a key player in the Indian pharmaceutical market since its inception in May 1956. Originally incorporated as Hoechst Fedco Pharma Private Limited, the company has undergone several name changes over the years, reflecting its evolution within the industry.
With a workforce exceeding 3,010 employees, Sanofi India operates a large-scale manufacturing facility in Goa and collaborates with 12 contract manufacturing organizations (CMOs) across India. Sanofi, through its wholly owned subsidiary Hoechst GmbH, holds a majority stake of 60.37% in Sanofi India, reinforcing its strategic alignment with the broader objectives of the parent company.
Financially, Sanofi India boasts a robust dividend yield of 6.78%, indicative of its commitment to shareholder value. Revenue is primarily derived from operations in India, which contribute 84.54% of the total, along with Singapore at 14.38%, with other regions accounting for 1.06% in FY23. The company focuses exclusively on pharmaceutical products, emphasizing its specialization and expertise in this sector.
Sanofi India follows a December year-end reporting cycle. In FY22, the company reported a slight decrease in revenue from operations, dropping to Rs. 2,770.1 crore from Rs. 2,956.60 crore in FY21. Net profits also saw a decline from Rs. 944.40 crore in FY21 to Rs. 620.60 crore in FY22. Noteworthy exceptional items included the sale of the nutraceutical business in FY21 and a distribution business deal in FY22.
In summary, Sanofi India stands as a prominent entity in the Indian pharmaceutical landscape, its strategic ownership, diversified operations, and consistent financial performance.
#2: Glenmark Life Sciences
In 2011, Glenmark Life Sciences was established, specializing in the production and development of active pharmaceutical ingredients (APIs) and offering contract development and manufacturing organization (CDMO) services. The company operates under Glenmark Pharmaceuticals, which holds an 82.84% ownership stake as of the December quarter.
Recently, Nirma received approval from the Competition Commission of India (CCI) to acquire Glenmark Life Sciences for Rs. 5,651.50 crore, at a rate of Rs. 615 per share. With a dividend yield of 5.30%, Glenmark Life Sciences generates revenue from diverse regions, with India contributing 52.42% and the rest of the world accounting for 47.57% in FY23. Revenue is primarily classified under the API segment.
For FY24, the company anticipates stable expansion despite a slightly lower growth projection. Notably, a CDMO agreement was inked with a minimum off-take commitment of $5 million, slated to commence commercial operations in 2024, as per recent Q3FY24 transcripts.
In FY23, Glenmark Life Sciences reported revenue from operations totaling Rs. 2,161.22 crore, marking a modest increase of 1.79% from the previous fiscal year. Net profits witnessed a more substantial uptick, reaching Rs. 466.96 crore compared to Rs. 418.72 crore, reflecting an 11.52% increase. Remarkably, the company maintained stable margins from FY19 to FY23, while achieving a commendable sales growth rate of 24.97% over the past four years.
In Summary
Investing in pharmaceutical stocks with high dividend yields can be a prudent strategy for income-oriented investors seeking stability and growth potential. Companies like Pfizer, Johnson & Johnson, and Merck & Co., Inc. have demonstrated their ability to generate consistent returns for shareholders while navigating the complexities of the healthcare industry.
When considering investment opportunities, it’s essential to conduct thorough research and assess each company’s financial health, dividend history, and growth prospects. By focusing on quality pharmaceutical stocks with attractive dividend yields, investors can build a resilient and rewarding investment portfolio.